Search

Your search keyword '"SteatoTest"' showing total 2 results
Start Over Descriptor "SteatoTest" Publication Type Electronic Resources
2 results on '"SteatoTest"'

1. JCM-Advances in Cardiology.

Author

Henein, Michael and Henein, Michael

Subjects
Medicine, Pharmacology, ACE2, COVID-19, CRT, Coptic clergy, Holter ECG, ICD, LMNA, ST segment elevation myocardial infarction, SteatoTest, adipokines, adiponectin, arrhythmias, cardiovascular disease, cardiovascular risk factors, dilated cardiomyopathy (DCM), extraction, hepatic steatosis, implantable cardioverter defibrillator, implantable loop recorder, lamin A, lamin C, major adverse events, metabolic-dysfunction-associated fatty liver disease (MAFLD), mortality, myocarditis, n/a, next generation sequencing (NGS), obesity, pacing, prevalence, primary percutaneous intervention, reimplantation, renin-angiotensin system, telemonitoring, visfatin
Abstract

Summary: Cardiology and cardiovascular sciences are two rapidly growing areas in medicine, with heart diseases being the number one cause of death worldwide. The last four decades have witnessed many developments in various cardiological sciences, including coronary artery disease, valve disease, heart failure, congenital heart diseases, and cardiovascular imaging, with a number of newly developed concepts, such as cardio-oncology, cardio-renal diseases, and preventive cardiology. This Special Issue (SI) of the Journal of Clinical Medicine, entitled "JCM-Advances in Cardiology", focuses on recent advances in the cardiological sciences. It published 8 research articles of significant clinical and scientific value.

2. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.

Author

Poynard, Thierry, Poynard, Thierry, Peta, Valentina, Munteanu, Mona, Charlotte, Frederic, Ngo, Yen, Ngo, An, Perazzo, Hugo, Deckmyn, Olivier, Pais, Raluca, Mathurin, Philippe, Myers, Rob, Loomba, Rohit, Ratziu, Vlad, FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group, Poynard, Thierry, Poynard, Thierry, Peta, Valentina, Munteanu, Mona, Charlotte, Frederic, Ngo, Yen, Ngo, An, Perazzo, Hugo, Deckmyn, Olivier, Pais, Raluca, Mathurin, Philippe, Myers, Rob, Loomba, Rohit, Ratziu, Vlad, and FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group

Abstract

BackgroundSerum biomarkers of steatosis such as the SteatoTest are recommended for large-scale screening studies, because imaging is less accessible and more expensive.AimsThe primary aim of this retrospective analysis of prospective studies was to construct a new SteatoTest-2 that was not inferior to the reference first-generation SteatoTest, but that did not include BMI or bilirubin, as these two components can increase test variability because of the assessment of weight and height and in case of Gilbert syndrome or hemolysis, respectively.Patients and methodsFive different subsets of 2997 patients with biopsies were evaluated for test construction and validation, and four to assess the prevalence of steatosis in target populations with increasing risks of steatosis. The performance of the SteatoTest-2 was compared with the reference test, using the noninferiority test (0.10 margin) and the Lin concordance coefficient.ResultsAreas under the receiver operating characteristic curve of the SteatoTest-2 were noninferior to the reference test (P<0.001). Areas under the receiver operating characteristic curve varied in the SteatoTest-2 and the reference test according to subsets and the prevalence of steatosis, with 0.772 [95% confidence interval (CI): 0.713-0.820] versus 0.786 (95% CI: 0.729-0.832) in the 2997 cases with biopsy and 0.822 (95% CI: 0.810-0.834) versus 0.868 (95% CI: 0.858-0.878) in the 5776 cases including healthy individuals without risk factors of steatosis as controls, respectively. The Lin coefficient was highly concordant (P<0.001), from 0.74 (95% CI: 0.74-0.74) in presumed NAFLD to 0.91 (95% CI: 0.89-0.93) in the construction subset.ConclusionThe SteatoTest-2 is simpler and noninferior to the first-generation SteatoTest for the diagnosis of steatosis, without the limitations of BMI and bilirubin.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results